Sinovac Biotech Stock Current Valuation
Valuation analysis of Sinovac Biotech helps investors to measure Sinovac Biotech's intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns.
Sinovac Biotech Company Current Valuation Analysis
Sinovac Biotech's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Sinovac Biotech Current Valuation | 614.58 M |
Most of Sinovac Biotech's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Sinovac Biotech is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
CompetitionIn accordance with the recently published financial statements, Sinovac Biotech has a Current Valuation of 614.58 M. This is 95.72% lower than that of the Healthcare sector and 86.77% lower than that of the Biotechnology industry. The current valuation for all United States stocks is 96.3% higher than that of the company.
Sinovac Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Sinovac Biotech's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Sinovac Biotech could also be used in its relative valuation, which is a method of valuing Sinovac Biotech by comparing valuation metrics of similar companies.Sinovac Biotech is currently under evaluation in current valuation category among related companies.
Sinovac Fundamentals
| Return On Equity | 11.03 | ||||
| Return On Asset | 4.53 | ||||
| Profit Margin | 10.02 % | ||||
| Operating Margin | 15.86 % | ||||
| Current Valuation | 614.58 M | ||||
| Shares Outstanding | 98.9 M | ||||
| Shares Owned By Insiders | 15.89 % | ||||
| Shares Owned By Institutions | 23.11 % | ||||
| Number Of Shares Shorted | 199.77 K | ||||
| Price To Earning | 48.65 X | ||||
| Price To Book | 2.29 X | ||||
| Price To Sales | 2.16 X | ||||
| Revenue | 213.17 M | ||||
| Gross Profit | 213.58 M | ||||
| EBITDA | 38.49 M | ||||
| Net Income | 15.35 M | ||||
| Cash And Equivalents | 176.72 M | ||||
| Cash Per Share | 1.79 X | ||||
| Total Debt | 93.13 M | ||||
| Debt To Equity | 0.28 % | ||||
| Current Ratio | 2.98 X | ||||
| Book Value Per Share | 2.83 X | ||||
| Cash Flow From Operations | 22.17 M | ||||
| Short Ratio | 47.51 X | ||||
| Earnings Per Share | 0.13 X | ||||
| Number Of Employees | 910 | ||||
| Beta | 0.08 | ||||
| Market Capitalization | 460.25 M | ||||
| Total Asset | 202.98 M | ||||
| Retained Earnings | (8.28 M) | ||||
| Working Capital | 70.52 M | ||||
| Current Asset | 128.52 M | ||||
| Current Liabilities | 58 M | ||||
| Z Score | 3.4 |
Currently Active Assets on Macroaxis
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in real. You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.
Other Consideration for investing in Sinovac Stock
If you are still planning to invest in Sinovac Biotech check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Sinovac Biotech's history and understand the potential risks before investing.
| CEOs Directory Screen CEOs from public companies around the world | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| AI Investment Finder Use AI to screen and filter profitable investment opportunities | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope |